# World Acceptance Corp: financial statements, quarterly

WRLD · Nasdaq · CIK 108385 · [Financials](/sectors/financials.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/wrld.md) · [Financials](/companies/wrld/financials.md) · [Filings](/companies/wrld/filings.md) · [Insiders](/companies/wrld/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wrld/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | Q4 FY2023 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | Q4 FY2024 (2025-03-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | Q4 FY2025 (2026-03-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [137](/filings/0000108385-25-000041.md) | [138](/filings/0000108385-25-000041.md) | [159](/filings/0000108385-25-000041.md) | [130](/filings/0000108385-26-000014.md) | [132](/filings/0000108385-26-000014.md) | [139](/filings/0000108385-26-000014.md) | [164](/filings/0000108385-26-000014.md) | [133](/filings/0000108385-26-000034.md) | [135](/filings/0000108385-26-000014.md) | [142](/filings/0000108385-26-000014.md) | [176](/filings/0000108385-26-000014.md) | [139](/filings/0000108385-26-000034.md) |
| Interest expense | $m | [12.5](/filings/0000108385-25-000041.md) | [11.7](/filings/0000108385-25-000041.md) | [11.8](/filings/0000108385-25-000041.md) | [9.8](/filings/0000108385-26-000014.md) | [10.5](/filings/0000108385-26-000014.md) | [11.3](/filings/0000108385-26-000014.md) | [11.2](/filings/0000108385-26-000014.md) | [9.6](/filings/0000108385-26-000034.md) | [14.3](/filings/0000108385-26-000014.md) | [12.8](/filings/0000108385-26-000014.md) | [12.7](/filings/0000108385-26-000014.md) | [11.4](/filings/0000108385-26-000034.md) |
| Income tax | $m | [4.8](/filings/0000108385-25-000041.md) | [2.9](/filings/0000108385-25-000041.md) | [11.6](/filings/0000108385-25-000041.md) | [3.1](/filings/0000108385-26-000014.md) | [5.9](/filings/0000108385-26-000014.md) | [2.7](/filings/0000108385-26-000014.md) | [10.4](/filings/0000108385-26-000014.md) | [0.7](/filings/0000108385-26-000034.md) | [0.4](/filings/0000108385-26-000014.md) | [(0.0)](/filings/0000108385-26-000014.md) | [9.6](/filings/0000108385-26-000014.md) | [1.8](/filings/0000108385-26-000034.md) |
| Net income | $m | [16.1](/filings/0000108385-25-000041.md) | [16.7](/filings/0000108385-25-000041.md) | [35.1](/filings/0000108385-25-000041.md) | [10.2](/filings/0000108385-26-000014.md) | [22.4](/filings/0000108385-26-000014.md) | [13.6](/filings/0000108385-26-000014.md) | [43.1](/filings/0000108385-26-000014.md) | [1.6](/filings/0000108385-26-000034.md) | [(1.7)](/filings/0000108385-26-000014.md) | [(0.6)](/filings/0000108385-26-000014.md) | [35.3](/filings/0000108385-26-000014.md) | [6.1](/filings/0000108385-26-000034.md) |
| Diluted EPS | $ per share | [2.71](/filings/0000108385-25-000041.md) | [2.84](/filings/0000108385-25-000041.md) | [6.09](/filings/0000108385-25-000041.md) | [1.82](/filings/0000108385-26-000014.md) | [4.03](/filings/0000108385-26-000014.md) | [2.49](/filings/0000108385-26-000014.md) | [7.91](/filings/0000108385-26-000014.md) | [0.30](/filings/0000108385-26-000034.md) | [(0.33)](/filings/0000108385-26-000014.md) | [(0.13)](/filings/0000108385-26-000014.md) | [7.44](/filings/0000108385-26-000014.md) | [1.33](/filings/0000108385-26-000034.md) |
| Basic EPS | $ per share | [2.78](/filings/0000108385-25-000041.md) | [2.89](/filings/0000108385-25-000041.md) | [6.19](/filings/0000108385-25-000041.md) | [1.85](/filings/0000108385-26-000014.md) | [4.09](/filings/0000108385-26-000014.md) | [2.51](/filings/0000108385-26-000014.md) | [8.11](/filings/0000108385-26-000014.md) | [0.30](/filings/0000108385-26-000034.md) | [(0.33)](/filings/0000108385-26-000014.md) | [(0.13)](/filings/0000108385-26-000014.md) | [7.53](/filings/0000108385-26-000014.md) | [1.36](/filings/0000108385-26-000034.md) |

- Revenue: us-gaap:Revenues
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | FY2023 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | FY2024 (2025-03-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | FY2025 (2026-03-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.8](/filings/0000108385-23-000065.md) | [12.8](/filings/0000108385-24-000004.md) | [5.2](/filings/0000108385-26-000014.md) | [11.1](/filings/0000108385-24-000038.md) | [9.7](/filings/0000108385-24-000062.md) | [10.3](/filings/0000108385-26-000005.md) | [4.7](/filings/0000108385-26-000034.md) | [3.0](/filings/0000108385-26-000034.md) | [14.9](/filings/0000108385-25-000092.md) | [10.0](/filings/0000108385-26-000005.md) | [6.1](/filings/0000108385-26-000034.md) | [10.4](/filings/0000108385-26-000034.md) |
| Total assets | $m | [1,106](/filings/0000108385-23-000065.md) | [1,120](/filings/0000108385-24-000004.md) | [1,056](/filings/0000108385-25-000041.md) | [1,048](/filings/0000108385-24-000038.md) | [1,049](/filings/0000108385-24-000062.md) | [1,111](/filings/0000108385-25-000008.md) | [1,008](/filings/0000108385-26-000014.md) | [1,024](/filings/0000108385-25-000075.md) | [1,062](/filings/0000108385-25-000092.md) | [1,142](/filings/0000108385-26-000005.md) | [1,054](/filings/0000108385-26-000034.md) | [1,079](/filings/0000108385-26-000034.md) |
| Total liabilities | $m | [696](/filings/0000108385-23-000065.md) | [713](/filings/0000108385-24-000004.md) | [632](/filings/0000108385-25-000041.md) | [626](/filings/0000108385-24-000038.md) | [632](/filings/0000108385-24-000062.md) | [682](/filings/0000108385-25-000008.md) | [571](/filings/0000108385-26-000014.md) | [596](/filings/0000108385-25-000075.md) | [697](/filings/0000108385-25-000092.md) | [791](/filings/0000108385-26-000005.md) | [703](/filings/0000108385-26-000034.md) | [717](/filings/0000108385-26-000034.md) |
| Long-term debt | $m | [564](/filings/0000108385-23-000065.md) | [588](/filings/0000108385-24-000004.md) | [498](/filings/0000108385-24-000024.md) | [495](/filings/0000108385-24-000038.md) | [507](/filings/0000108385-24-000062.md) | [561](/filings/0000108385-25-000008.md) | [448](/filings/0000108385-25-000041.md) | [472](/filings/0000108385-25-000075.md) | [585](/filings/0000108385-25-000092.md) | [677](/filings/0000108385-26-000005.md) | [587](/filings/0000108385-26-000014.md) | [573](/filings/0000108385-26-000034.md) |
| Shareholders' equity | $m | [410](/filings/0000108385-25-000008.md) | [407](/filings/0000108385-25-000008.md) | [422](/filings/0000108385-26-000014.md) | [423](/filings/0000108385-25-000092.md) | [417](/filings/0000108385-26-000005.md) | [428](/filings/0000108385-26-000005.md) | [437](/filings/0000108385-26-000034.md) | [426](/filings/0000108385-26-000034.md) | [366](/filings/0000108385-26-000005.md) | [352](/filings/0000108385-26-000005.md) | [351](/filings/0000108385-26-000034.md) | [362](/filings/0000108385-26-000034.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | Q4 FY2023 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | Q4 FY2024 (2025-03-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | Q4 FY2025 (2026-03-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [63.4 d](/filings/0000108385-24-000062.md) | [58.9 d](/filings/0000108385-25-000008.md) | [83.8 d](/filings/0000108385-26-000014.md) | [48.4](/filings/0000108385-25-000075.md) | [53.8 d](/filings/0000108385-25-000092.md) | [61.1 d](/filings/0000108385-26-000005.md) | [90.9 d](/filings/0000108385-26-000014.md) | [58.2](/filings/0000108385-26-000034.md) | [48.6 d](/filings/0000108385-25-000092.md) | [58.0 d](/filings/0000108385-26-000005.md) | [94.6 d](/filings/0000108385-26-000014.md) | [64.4](/filings/0000108385-26-000034.md) |
| Capital expenditure | $m | [1.5 d](/filings/0000108385-24-000062.md) | [1.2 d](/filings/0000108385-25-000008.md) | [1.5 d](/filings/0000108385-26-000014.md) | [1.1](/filings/0000108385-25-000075.md) | [1.0 d](/filings/0000108385-25-000092.md) | [0.7 d](/filings/0000108385-26-000005.md) | [0.9 d](/filings/0000108385-26-000014.md) | [1.0](/filings/0000108385-26-000034.md) | [0.9 d](/filings/0000108385-25-000092.md) | [0.8 d](/filings/0000108385-26-000005.md) | [1.1 d](/filings/0000108385-26-000014.md) | [1.3](/filings/0000108385-26-000034.md) |
| Share repurchases | $m | [0.0 d](/filings/0000108385-24-000062.md) | [17.3 d](/filings/0000108385-25-000008.md) | [18.9 d](/filings/0000108385-26-000014.md) | [11.1](/filings/0000108385-25-000075.md) | [10.0 d](/filings/0000108385-25-000092.md) | [1.0 d](/filings/0000108385-26-000005.md) | [32.0 d](/filings/0000108385-26-000014.md) | [13.0](/filings/0000108385-26-000034.md) | [66.6 d](/filings/0000108385-25-000092.md) | [15.0 d](/filings/0000108385-26-000005.md) | [37.8 d](/filings/0000108385-26-000014.md) | [2.2](/filings/0000108385-26-000034.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-09-30) | Q3 FY2022 (2022-12-31) | Q1 FY2023 (2023-06-30) | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [5,726](/filings/0000108385-23-000065.md) | [5,857](/filings/0000108385-24-000004.md) | [5,891](/filings/0000108385-24-000038.md) | [5,939](/filings/0000108385-24-000062.md) | [5,860](/filings/0000108385-25-000008.md) | [5,568](/filings/0000108385-25-000075.md) | [5,549](/filings/0000108385-25-000092.md) | [5,464](/filings/0000108385-26-000005.md) | [5,289](/filings/0000108385-26-000034.md) | [5,093](/filings/0000108385-25-000092.md) | [4,759](/filings/0000108385-26-000005.md) | [4,581](/filings/0000108385-26-000034.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,663,180 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0000108385-26-000034.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.